IntelGenx Corp. has recently announced a groundbreaking research collaboration with Karolinska University Hospital. The focus of this collaboration is to explore the potential of using Montelukast VersaFilm® as a treatment for Parkinson's Disease. Led by the esteemed Professor Per Svenningsson, an expert in clinical neuroscience, this study will delve into the efficacy of IntelGenx's innovative film in doses exceeding 40 mg.
Montelukast VersaFilm® offers a significant advantage over traditional tablets due to its more convenient dosing method. Unlike tablets that require multiple administrations throughout the day, this film provides a simpler and more user-friendly approach to medication intake.
Upon completion of the study, IntelGenx will have the opportunity to acquire both the intellectual property rights and valuable study data. This further emphasizes their commitment to advancing medical treatments and addressing unmet needs in healthcare.
As a leading drug delivery company, IntelGenx specializes in developing pharmaceutical films that aim to revolutionize patient care. Their partnership with Karolinska University Hospital marks another significant step towards improving